# FDA Clears Alzheimer’s Blood Test for Symptomatic Adults 40 and Older

> PrecivityAD2 may help estimate amyloid pathology during a clinical evaluation, but it is neither general screening nor a stand-alone Alzheimer’s diagnosis.

_Source: Independent medical-device coverage confirms FDA clearance; ADDF provides context while disclosing its investment in C2N. · 2026-08-21 · 7 min read · Verified against primary sources_

Canonical: https://iyu.app/e/precivityad2-alzheimers-blood-test-clearance

## The 60-second version

The FDA cleared PrecivityAD2 to help evaluate symptomatic adults age 40 and older, not to screen the general population.

**Key points**

- The test uses blood biomarkers to estimate amyloid pathology.
- Results must be interpreted within a broader clinical evaluation.
- A positive or abnormal result is not a stand-alone Alzheimer’s diagnosis and does not by itself justify treatment.
- The reported 1,142-subject study count is attributed to Clinical Trial Vanguard because performance values were not provided here.
- ADDF’s contextual claims are disclosed alongside its financial interest as an investor in C2N.

**Verdict.** The clearance broadens access to a diagnostic aid, but its value depends on selecting appropriate symptomatic patients and interpreting results clinically.

## Full explainer

The FDA has cleared C2N Diagnostics’ PrecivityAD2 for adults age 40 and older who have signs or symptoms of cognitive impairment and are being evaluated for Alzheimer’s disease or another cause of cognitive decline. The clearance does not authorize population-wide screening, establish a diagnosis by itself, or show that treatment should begin.


### Scope — Who the clearance covers

- **40+** — Minimum indicated age, provided cognitive symptoms or signs are present
- **1,142** — Study participants reported by Clinical Trial Vanguard
- **3** — FDA-cleared Alzheimer’s blood tests now counted by ADDF
- **15–20 years** — Possible lead time between pathology and symptoms cited by ADDF as context


### Interpretation — What the test contributes

- **What it measures:** Blood biomarkers used to estimate whether amyloid pathology is present.
- **Intended setting:** A clinical evaluation of a symptomatic adult age 40 or older.
- **What it can support:** A clinician’s assessment of Alzheimer’s disease or other possible causes of cognitive decline.
- **What it cannot establish:** A stand-alone diagnosis, a reason to start treatment, or a recommendation to screen healthy adults.
- **Possible next step:** Clinical interpretation and, when appropriate, follow-up evaluation or testing.


### Limits — Clearance does not remove clinical judgment

> **⚑ Caveat:** Clinical Trial Vanguard reports that the supporting clinical study included 1,142 subjects; no sensitivity or specificity values were supplied in the evidence used here, so no performance estimate should be inferred. ADDF says three Alzheimer’s blood tests are now FDA-cleared and that pathology may precede symptoms by 15–20 years, but ADDF also discloses that it invested in C2N. Those figures are attributed context, not evidence that earlier testing improves outcomes. Independent medical-device reports confirm the clearance and the indicated age range.

> **i** People with cognitive symptoms should discuss a structured evaluation with a qualified clinician. Healthy people without symptoms should not treat this clearance as an invitation to order or pursue self-screening.


## Primary sources

- [ADDF announcement](https://www.prnewswire.com/news-releases/fda-clearance-of-c2n-diagnostics-precivityad2-blood-test-advances-precision-medicine-for-alzheimers-building-on-groundwork-laid-by-early-addf-investment-302856858.html)
- [Clinical Trial Vanguard analysis](https://www.clinicaltrialvanguard.com/news/fda-clears-precivityad2-blood-test-for-alzheimers-in-adults-as-young-as-40/)
- [Medical Device Network report](https://www.medicaldevice-network.com/news/fda-clears-c2n-diagnostics-early-alzheimer-assessment-test/)

---
_Published by iyu (https://iyu.app) — the day's AI news, checked against primary sources and rewritten in plain language. Free to quote with attribution and a link to the canonical URL._